Moolec Science SA Financials
This page shows Moolec Science SA (MLECW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 3 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Moolec’s operating model still depends on outside funding, because recent growth has not yet become self-financing cash generation.
Liquidity improved as the current ratio moved from 0.4x to 1.7x. But that cushion was financed, not earned: operating cash flow was-$9.3M while financing inflow was$11.7M .
The balance sheet is more constrained by operating obligations than by lenders. Total liabilities reached
FY2024 also looks like a working-capital build, not a clean cash-conversion year. Inventory stood at
Financial Health Signals
Based on FY2024 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Moolec Science SA's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Moolec Science SA carries a low D/E ratio of 0.04, meaning only $0.04 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
Moolec Science SA's current ratio of 1.69 indicates adequate short-term liquidity, earning a score of 30/100. The company can meet its near-term obligations, though with limited headroom.
While Moolec Science SA generated -$9.3M in operating cash flow, capex of $158K consumed most of it, leaving -$9.5M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Moolec Science SA generates a -107.3% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -512.5% the prior year.
Moolec Science SA passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Moolec Science SA generates $1.28 in operating cash flow (-$9.3M OCF vs -$7.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Moolec Science SA generated $5.6M in revenue in fiscal year 2024. This represents an increase of 521.5% from the prior year.
Moolec Science SA reported -$7.3M in net income in fiscal year 2024. This represents an increase of 85.9% from the prior year.
Cash & Balance Sheet
Moolec Science SA generated -$9.5M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 26.0% from the prior year.
Moolec Science SA held $5.4M in cash against $249K in long-term debt as of fiscal year 2024.
Moolec Science SA had 38M shares outstanding in fiscal year 2024. This represents an increase of 2.3% from the prior year.
Margins & Returns
Moolec Science SA's net profit margin was -130.0% in fiscal year 2024, showing the share of revenue converted to profit. This is up 5592.2 percentage points from the prior year.
Moolec Science SA's ROE was -107.3% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 405.2 percentage points from the prior year.
Capital Allocation
Moolec Science SA invested $158K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents an increase of 967.7% from the prior year.
MLECW Income Statement
| Metric | Q2'25 | Q4'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6M | N/A | $252K-85.5% | $1.7M | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | $9K | N/A | $11K+86.3% | $6K | N/A | $86K | N/A | -$3K |
| Income Tax | $281K | N/A | -$236K-9.6% | -$215K | N/A | N/A | N/A | N/A |
| Net Income | -$2.4M | N/A | -$1.8M-12.1% | -$1.6M | N/A | N/A | N/A | -$721K |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
MLECW Balance Sheet
| Metric | Q2'25 | Q4'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $31.4M-9.8% | $34.8M | N/A | $22.5M-6.5% | $24.1M+20.4% | $20.0M-13.8% | $23.2M | N/A |
| Current Assets | $9.5M-30.6% | $13.7M | N/A | $3.2M-40.0% | $5.3M-25.5% | $7.2M-31.4% | $10.4M | N/A |
| Cash & Equivalents | $1.9M-64.2% | $5.4M | N/A | $854K-66.2% | $2.5M-59.4% | $6.2M-40.4% | $10.4M | N/A |
| Inventory | $4.8M-22.8% | $6.3M+1151.9% | $502K+28.5% | $390K-16.2% | $466K | N/A | N/A | N/A |
| Accounts Receivable | $809K-20.0% | $1.0M | N/A | N/A | $1.3M | N/A | N/A | N/A |
| Goodwill | $281K+7.0% | $263K | N/A | $248K-1.3% | $251K-94.7% | $4.7M | N/A | N/A |
| Total Liabilities | $28.6M+2.2% | $28.0M | N/A | $13.6M-2.5% | $13.9M+66.1% | $8.4M-25.6% | $11.3M | N/A |
| Current Liabilities | $6.5M-20.8% | $8.2M | N/A | $12.5M-0.7% | $12.6M+50.1% | $8.4M-25.6% | $11.3M | N/A |
| Long-Term Debt | $166K-33.1% | $249K | N/A | $244K | N/A | $2K+47.4% | $1K | N/A |
| Total Equity | $2.8M-59.0% | $6.8M+2.0% | $6.7M-24.8% | $8.9M-12.0% | $10.1M-12.8% | $11.6M-2.6% | $11.9M+1247.6% | $883K |
| Retained Earnings | -$70.3M-6.6% | -$65.9M | N/A | -$60.2M-2.7% | -$58.6M-4.9% | -$55.9M-0.6% | -$55.5M | N/A |
MLECW Cash Flow Statement
| Metric | Q2'25 | Q4'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | N/A | N/A | -$3.9M-123.9% | -$1.7M+34.6% | -$2.7M+37.5% | -$4.3M-619.4% | -$593K-6242.9% | $10K |
| Capital Expenditures | N/A | N/A | -$8K-107.2% | $104K+752.3% | $12K | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | -$3.9M-111.7% | -$1.8M+31.0% | -$2.7M | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | -$2.2M-2557.2% | -$82K | N/A | N/A |
| Financing Cash Flow | N/A | N/A | $4.8M+3882.0% | -$127K-109.9% | $1.3M | $0 | N/A | N/A |
| Dividends Paid | N/A | N/A | N/A | N/A | $0 | $0 | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
MLECW Financial Ratios
| Metric | Q2'25 | Q4'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 | Q2'23 | Q1'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -91.8% | N/A | -707.4%-616.0pp | -91.4% | N/A | N/A | N/A | N/A |
| Return on Equity | -86.8% | N/A | -26.7%-8.8pp | -17.9% | N/A | N/A | N/A | -81.7% |
| Return on Assets | -7.7% | N/A | N/A | -7.1% | N/A | N/A | N/A | N/A |
| Current Ratio | 1.48-0.2 | 1.69 | N/A | 0.26-0.2 | 0.42-0.4 | 0.85-0.1 | 0.93 | N/A |
| Debt-to-Equity | 0.06+0.0 | 0.04 | N/A | 0.03-1.4 | 1.38+1.4 | 0.000.0 | 0.00 | N/A |
| FCF Margin | N/A | N/A | -1551.6%-1445.4pp | -106.2% | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Moolec Science SA's annual revenue?
Moolec Science SA (MLECW) reported $5.6M in total revenue for fiscal year 2024. This represents a 521.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Moolec Science SA's revenue growing?
Moolec Science SA (MLECW) revenue grew by 521.5% year-over-year, from $905K to $5.6M in fiscal year 2024.
Is Moolec Science SA profitable?
No, Moolec Science SA (MLECW) reported a net income of -$7.3M in fiscal year 2024, with a net profit margin of -130.0%.
How much debt does Moolec Science SA have?
As of fiscal year 2024, Moolec Science SA (MLECW) had $5.4M in cash and equivalents against $249K in long-term debt.
What is Moolec Science SA's net profit margin?
Moolec Science SA (MLECW) had a net profit margin of -130.0% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Moolec Science SA's return on equity (ROE)?
Moolec Science SA (MLECW) has a return on equity of -107.3% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is Moolec Science SA's free cash flow?
Moolec Science SA (MLECW) generated -$9.5M in free cash flow during fiscal year 2024. This represents a -26.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Moolec Science SA's operating cash flow?
Moolec Science SA (MLECW) generated -$9.3M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Moolec Science SA's total assets?
Moolec Science SA (MLECW) had $34.8M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Moolec Science SA's capital expenditures?
Moolec Science SA (MLECW) invested $158K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
What is Moolec Science SA's current ratio?
Moolec Science SA (MLECW) had a current ratio of 1.69 as of fiscal year 2024, which is generally considered healthy.
What is Moolec Science SA's debt-to-equity ratio?
Moolec Science SA (MLECW) had a debt-to-equity ratio of 0.04 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Moolec Science SA's return on assets (ROA)?
Moolec Science SA (MLECW) had a return on assets of -21.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Moolec Science SA's cash runway?
Based on fiscal year 2024 data, Moolec Science SA (MLECW) had $5.4M in cash against an annual operating cash burn of $9.3M. This gives an estimated cash runway of approximately 7 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Moolec Science SA's Piotroski F-Score?
Moolec Science SA (MLECW) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Moolec Science SA's earnings high quality?
Moolec Science SA (MLECW) has an earnings quality ratio of 1.28x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Moolec Science SA?
Moolec Science SA (MLECW) scores 22 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.